Table 2.
Multivariate analysis of correlates with HHV8 lytic and latent antibody seropositivities among study participants
| Characteristics/Risk factor | LANA
|
ORF65
|
||||
|---|---|---|---|---|---|---|
| Positives/total (%) | OR (95%CI)* | p-value* | Positives/total (%) | OR (95% CI)* | p-value* | |
| Socio-demographics | ||||||
| Gender | ||||||
| Male | 11/170 (6.5) | 1.00 | 18/170 (10.6) | 1.00 | ||
| Female | 22/146 (15.1) | 2.53 (1.12–5.73) | 0.026* | 22/146 (15.1) | 1.38 (0.67–2.85) | 0.385 |
| Age group | ||||||
| 0–18 | 2/11 (18.2) | 1.00 | 3/11 (27.3) | 1.00 | ||
| 19–49 | 24/243 (10.3) | 0.36 (0.06–2.16) | 0.265 | 30/234 (12.8) | 0.33 (0.07–1.60) | 0.172 |
| 50 + | 7/71 (9.9) | 0.38 (0.05–2.74) | 0.340 | 7/71 (9.9) | 0.28 (0.05–1.65) | 0.162 |
| HIV-related factors | ||||||
| ART | ||||||
| Yes | 19/238 (8.0) | 1.00 | 22/238 (9.2) | 1.00 | ||
| No | 14/78 (17.9) | 3.77 (1.55–9.14) | 0.003** | 18/78 (23.1) | 3.79 (1.71–8.42) | 0.001** |
| CD4 (cell/mm3) | ||||||
| > 200 | 15/187 (8.0) | 1.00 | 22/187 (11.8) | 1.00 | ||
| ≤ 200 | 18/129 (14.0) | 3.53 (1.44–8.64) | 0.006** | 18/129 (14.0) | 2.12 (0.94–4.78) | 0.07 |
| CD8 (cell/mm3) | ||||||
| > 400 | 27/251 (10.8) | 1.00 | 32/251 (12.7) | 1.00 | ||
| ≤ 400 | 6/65 (9.2) | 0.73 (0.25–2.14) | 0.571 | 8/65 (12.3) | 0.97 (0.37–2.57) | 0.955 |
| Viral load (copies/mL) | ||||||
| ≤ 400 | 4/25 (16.0) | 1.00 | 6/25 (24.0) | 1.00 | ||
| > 400 | 29/291 (10.0) | 0.47 (0.12–1.86) | 0.287 | 34/291 (11.7) | 0.42 (0.13–1.35) | 0.143 |
| Duration of HIV infection (yr) | ||||||
| ≤ 10 | 14/97 (14.4) | 1.00 | 18/97 (18.6) | 1.00 | ||
| > 10 | 19/219 (8.7) | 0.59 (0.25–1.38) | 0.220 | 22/219 (10.0) | 0.54 (0.25–1.19) | 0.129 |
| Co-infections | ||||||
| HBsAg | ||||||
| Negative | 29/293 (9.9) | 1.00 | 35/293 (11.9) | 1.00 | ||
| Positive | 4/23 (17.4) | 2.36 (0.67–8.47) | 0.182 | 5/23 (21.7) | 2.41 (0.75–7.72) | 0.140 |
| HCV | ||||||
| Negative | 10/81 (12.3) | 1.00 | 13/81 (16.0) | 1.00 | ||
| Positive | 23/235 (9.8) | 0.52 (0.89–1.44) | 0.211 | 27/235 (11.5) | 0.63 (0.25–1.58) | 0.323 |
| EBV | ||||||
| Negative | 2/24 (8.3) | 1.00 | 4/24 (16.7) | 1.00 | ||
| Positive | 31/292 (10.6) | 1.88 (0.36–9.72) | 0.452 | 36/292 (12.3) | 0.93 (0.27–3.25) | 0.909 |
| HSV-1 | ||||||
| Negative | 8/80 (10.0) | 1.00 | 9/80 (11.3) | 1.00 | ||
| Positive | 25/236 (10.6) | 1.30 (0.52–3.24) | 0.574 | 31/236 (13.1) | 1.42 (0.60–3.36) | 0.427 |
| HSV-2 | ||||||
| Negative | 26/251 (10.4) | 1.00 | 32/251 (12.7) | 1.00 | ||
| Positive | 7/65 (10.8) | 1.03 (0.39–2.73) | 0.956 | 8/65 (12.3) | 0.95 (0.38–2.37) | 0.917 |
*
The odds ratio (OR) and 95% CI were obtained by adjusting for other variables listed in the table.